Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

BACKGROUND: In developing countries, the treatment of hemophilia patients with inhibitors is presently the most challenging and serious issue in hemophilia management, direct costs of clotting factor concentrates accounting for >98% of the highest economic burden absorbed for the health care of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasekh, Hamid Reza, Imani, Ali, Karimi, Mehran, Golestani, Mina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234155/
https://www.ncbi.nlm.nih.gov/pubmed/22163168
http://dx.doi.org/10.2147/CEOR.S25909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234155/
https://www.ncbi.nlm.nih.gov/pubmed/22163168
http://dx.doi.org/10.2147/CEOR.S25909

Ejemplares similares